What Is Efocipegtrutide? Definition and What Research Reports

Efocipegtrutide is the international nonproprietary name of an investigational peptide that also appears in the published literature under the development code HM15211. It is described as a single-molecule, long-acting agonist engineered to act at more than one incretin-family receptor — the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors — which places it inside the group of molecules that review articles call multifunctional incretin peptides, incretin co-agonists, or tri-agonists (review of multifunctional incretin peptides in type 2 diabetes and obesity). In the clinical literature the compound has appeared most prominently in metabolic liver disease: researchers published the design and rationale of a phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis, known as the HM-TRIA-201 study (HM-TRIA-201 design and rationale paper). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition or treatment.

What class of molecule the term refers to

Efocipegtrutide is a peptide-based receptor agonist rather than a small molecule. The -tide suffix in its nonproprietary name follows the standard naming convention for peptide drugs, and the internal peg element follows the convention used for molecules carrying a polyethylene glycol–based conjugation intended to extend circulating half-life. Long-acting engineering of this type is a defining feature of the wider class: review articles describing multifunctional incretin peptides have grouped together molecules that combine activity at two or three incretin and glucagon-family receptors within one sequence, in contrast to earlier single-receptor agonists (multifunctional incretin peptide review, 2025).

Related vocabulary

How the term is used in peptide research

In scientific writing, "efocipegtrutide" and "HM15211" are used interchangeably, with the code name more common in trial protocols and registry entries and the nonproprietary name more common in review articles and pharmacology summaries. Readers scanning the literature will usually encounter the term in one of three contexts:

• As a class example. Reviews of multifunctional incretin peptides list named tri-agonists when explaining why developers moved from single-receptor to multi-receptor designs for type 2 diabetes, obesity and associated co-morbidities (multifunctional incretin peptide review, 2025).
• As a trial compound. The compound is named as the investigational agent in the 52-week, adaptive randomized, double-blind, placebo-controlled, multicenter HM-TRIA-201 study in patients with biopsy-confirmed non-alcoholic steatohepatitis (HM-TRIA-201 design and rationale).
• As part of the cardiometabolic co-agonist landscape. Broader reviews of incretin co-agonists have examined efficacy and safety across this drug class in cardiometabolic care (incretin co-agonist review, World Journal of Cardiology, 2025).

What the published literature reports

The published record on this specific molecule is narrower than the record on approved incretin medicines, and most of what is citable is descriptive rather than outcome data. The HM-TRIA-201 paper was a design and rationale publication: researchers set out the structure of a phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter study running 52 weeks in patients whose non-alcoholic steatohepatitis was confirmed by biopsy, rather than reporting final efficacy results in that paper (HM-TRIA-201 design and rationale, 2023). Design papers of this kind explain eligibility, randomization and planned assessments so that later results publications can be interpreted against a pre-specified plan.

At the class level, a 2025 review examined multifunctional incretin peptides as therapies for type 2 diabetes, obesity and associated co-morbidities, describing the rationale for combining GLP-1, GIP and glucagon receptor activity within one peptide (Peptides, 2025). A separate 2025 review assessed the efficacy and safety of incretin co-agonists as advances in cardiometabolic healthcare, covering both the benefits and the safety considerations reported for the class (World Journal of Cardiology, 2025). Neither review is a substitute for compound-specific trial results, and this entry does not attribute any numerical efficacy figure to efocipegtrutide, because the sources verified for this page do not supply one.

Safety and Tolerability: What Studies Report

Because the trial publication cited here described a study design rather than completed outcomes, it did not report an adverse-event tally for the compound; instead it laid out the 52-week placebo-controlled framework within which safety and efficacy were to be assessed in biopsy-confirmed non-alcoholic steatohepatitis (HM-TRIA-201 design and rationale). At the class level, researchers who reviewed incretin co-agonists explicitly paired efficacy with safety when summarising this group of agents in cardiometabolic medicine (incretin co-agonist review, 2025), and the broader review of multifunctional incretin peptides discussed the class in the setting of type 2 diabetes, obesity and their co-morbidities (Peptides, 2025). Anyone assessing tolerability for a specific molecule would need the primary results publication for that molecule, not a class review.

What this entry does not cover

This glossary entry is definitional. It does not describe amounts, schedules, routes, combinations or sequencing, and it does not compare efocipegtrutide with any approved medicine on outcomes, because such comparisons are not supported by the sources verified for this page. No dose figure is stated here at all, for the same reason: the verified literature summarised above does not place one within scope.

On regulatory status, the papers cited describe efocipegtrutide as an investigational compound studied in clinical trials; none of them describes an approved product bearing this name. Peptides encountered in research supply channels are frequently labelled "research use only" (RUO), which is a labelling and distribution category rather than an indication that a substance has been evaluated for human use. Readers comparing an investigational peptide with an approved medicine should treat the two categories as distinct.

Quick reference

1. Name: efocipegtrutide; development code HM15211 (HM-TRIA-201 design paper).
2. Type: long-acting peptide agonist acting at more than one incretin-family receptor, within the multifunctional incretin peptide class (Peptides, 2025).
3. Main clinical setting in the cited literature: a 52-week phase 2, placebo-controlled study in biopsy-confirmed non-alcoholic steatohepatitis (HM-TRIA-201 design paper).
4. Class context: reviewed alongside other incretin co-agonists for cardiometabolic disease (World Journal of Cardiology, 2025).

Again, this page is educational only and is not medical advice; decisions about any therapy belong with a licensed physician who knows the individual case.

References

• Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities (Peptides, 2025)
• A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis — Study design and rationale of HM-TRIA-201 study (Contemporary Clinical Trials, 2023)
• Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare (World Journal of Cardiology, 2025)